Chris Boshoff, top oncology executive, counts on gains from the $43 billion Seagen merger.

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Mere inability to use a room thus does not amount to direct physical loss of the room. Moreover, the policy expressly ...

Pfizer PFE and partner BioNTech BNTX announced that a phase III study evaluating an mRNA-based combination vaccine candidate ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A combination Covid-flu vaccination developed by Pfizer Inc. and BioNTech SE missed on one of its goals in a final-stage ...

Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 ...

Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against ...

Lofty expectations for continuing sales of vaccines and antivirals have fallen short, sending Pfizer’s stock price tumbling ...